⁍ An independent data monitoring panel recommended placing on hold enrolment to its trial for COVID-19 antibody treatment in hospitalized patients.
⁍ The committee, however, backed the enrolment in non-hospitalized patients as well as hospitalized patients requiring either no or low-flow oxygen.
– A major rheumatoid arthritis drug trial is on hold after an independent panel recommended it be put on hold for patients who need high-flow oxygen or mechanical ventilation in the hospital, Reuters reports. Regeneron Pharmaceuticals said on Friday an independent data monitoring panel recommended placing on hold enrollment to its trial for COVID-19 antibody treatment in hospitalized patients requiring high-flow oxygen or mechanical ventilation. The committee, however, backed the enrolment in non-hospitalized patients as well as hospitalized patients requiring either no or low-flow oxygen.
Source: https://www.reuters.com/article/health-coronavirus-regeneron-pharms/refile-regeneron-to-not-enrol-covid-19-patients-in-need-of-ventilators-for-antibody-trial-idUSL4N2HL4HL